Self injector developer and manufacturer SHL Medical has inaugurated its new US manufacturing facility in North Charleston, South Carolina.
The Swiss company built the 360,000 sqft automated facility to cater to the global demand for cardiometabolic autoinjectors, with GLP-1 receptor agonist prescriptions continuing to skyrocket worldwide.
This follows Trump's plans to impose tariffs on pharmaceutical goods from as early as April 2.
SHL Medical's facility will be responsible for the manufacture of the company's autoinjector range, which are used to deliver medications targeting endocrine, dermatological and musculoskeletal conditions — to name a few.
Through the inauguration of this facility, SHL Medical will enhance its production capacity, while also boosting its supply chain in the key North American market.
"US-based production is a major step forward in our global expansion," noted Ulrich Faessler, CEO & Chairman of SHL Medical.
"With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers."
The facility has already created more than 300 jobs for local residents — utilising medical device injection molding technology and automated assembly to boost efficiency and product quality.
The North Charleston operations will run in tandem with the company's final assembly, packaging and labelling facility in Deerfield Beach, Florida — allowing the company to deliver around 1.5 billion devices to customers this year alone.
"The most trusted autoinjector brand is now made in the USA. We are proud to be contributing to the growth of the local economy and becoming a key player in the area while contributing to our sustainability goals." adds Kimberlee Steele, Managing Director North America at SHL Medical.